![Unquote](/images/site-logo.png)
Oxford Immunotec closes £7M series B financing
Oxford Immunotec, the T cell diagnostics company, has announced that it has closed a £7M series B private equity financing. The round was led by Prelude Ventures, who invested £2.75M, alongside Quester, the Dow Chemical Company, and Top Technology. Oxford Immunotec will use the financing to extend marketing for its first product, T SPOT™-TB, a diagnostic test for tuberculosis (TB), currently approved for sale in Europe.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater